“Huntingtin holiday”: progress toward an antisense therapy for Huntington's disease
Lowering mutant Huntingtin is a consensus therapeutic strategy for Huntington's disease. In
this issue of Neuron, Kordasiewicz et al.(2012) show the benefit of transient antisense
oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic
benefit in HD mice.
this issue of Neuron, Kordasiewicz et al.(2012) show the benefit of transient antisense
oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic
benefit in HD mice.
Lowering mutant Huntingtin is a consensus therapeutic strategy for Huntington's disease. In this issue of Neuron, Kordasiewicz et al. (2012) show the benefit of transient antisense oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic benefit in HD mice.
cell.com
